Compare BridgeBio Pharma Inc (BBIO) vs Brunswick Corporation (BC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Brunswick Corporation — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Brunswick Corporation trades at $81.32 (market cap $5.21B). The key difference: BridgeBio Pharma Inc is far larger — about 3.2× Brunswick Corporation's market cap, and Brunswick Corporation pays a 2.19% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | BC | |
|---|---|---|
Market Cap | $16.61B | $5.21B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $89.22 |
52-Week Low | $47.29 | $56.70 |
Enterprise Value | $18.16B | $7.21B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
BC trades at $81.55, up 0.37% with a bullish technical signal. Recent Q2 2026 earnings beat estimates with EPS of $1.56 versus $1.19 expected. The company maintains a dividend of $0.44 per share and has strong analyst support with 22 buy ratings. However, negative net income margin and ROE highlight profitability challenges amid declining revenue trends from $6.8B in 2022 to $5.4B in 2025.
Outlook is cautiously optimistic due to earnings beats and institutional buying, but high P/E of 73.92 and persistent net losses pose valuation and execution risks. The consensus price target of $85.33 suggests modest upside, contingent on reversing profit declines and stabilizing cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Brunswick Corporation
Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines
Read more on BC →
